N-Acetyl-DL-glutamic acid is the racemic N-acetyl derivative of DL-glutamic acid, supplied as a white to off-white crystalline powder with CAS registry number 19146-55-5, molecular formula C₇H₁₁NO₅, and molecular weight 189.17 g mol⁻¹. The compound is listed in synthesis catalogues as Ac-DL-Glu-OH and 2-acetamidopentanedioic acid. Because the molecule retains two free carboxylic acid groups, aqueous solubility is pH-dependent: below pH 2.0 the unionized form dominates, while above pH 6.5 the disodium salt becomes readily soluble. Preparative stock solutions are commonly prepared by suspending the powder in deionized water and adding 1 mol L⁻¹ sodium hydroxide until the pH stabilizes between 6.5 and 7.5, a range below the conditions that accelerate base-catalysed cleavage of the acetamide group. The product is not a single enantiomer; it consists of 50:50 molar proportions of N-acetyl-L-glutamic acid and N-acetyl-D-glutamic acid, and its specific rotation at the sodium D-line is 0.0° (c = 1, water, 20 °C). The racemic composition does not imply chemical inertness; it reflects cancellation of the equal and opposite optical contributions of the two enantiomers.

Commercial differentiation of N-acetyl-DL-glutamic acid depends on release specifications rather than a single model number. Reagent-grade material is routinely released with assay ≥98.0% by HPLC, while high-purity bulk material may be released with assay ≥99.0% and tighter elemental impurity limits. Because no USP, Ph. Eur., or JP monograph exists specifically for the DL racemate, a manufacturer’s designation of “pharmaceutical intermediate grade” should be verified against ICH Q3C residual solvent limits and ICH Q3D elemental impurity limits. Certificates of analysis must therefore include method-specific data rather than a nominal purity statement alone. The analytical profile is typically established using chromatographic purity, loss on drying, residue on ignition, and optical rotation. For a purchase order intended to support drug master file development, the appropriate documentation is a multi-page certificate of analysis linked to a validated batch record.

For preparative synthesis, the most common route is acetylation of DL-glutamic acid with acetic anhydride in aqueous alkaline solution. In a jacketed glass-lined reactor, DL-glutamic acid is charged into water, adjusted to pH 9.0–9.5, and treated with acetic anhydride below 25 °C because the acylation exotherm can raise the batch temperature rapidly. The pH is maintained between 8.0 and 9.5 by sodium hydroxide addition; below pH 8.0 the reaction rate decreases, while above pH 10.5 hydrolysis of the newly formed acetyl group becomes significant. After acylation, the mixture is acidified with hydrochloric acid to pH 2.0–2.5 to precipitate crude N-acetyl-DL-glutamic acid, which is then recrystallized from hot water or an ethanol-water mixture. This route explains the common process impurities: residual DL-glutamic acid, acetic acid, sodium chloride, and residual alcohol. Production-scale material may contain chloride in the range 0.1–0.5% before washing; insufficient removal elevates residue on ignition and can interfere with later metal-sensitive catalytic steps.

Are the Typical Release Specifications of N-Acetyl-DL-Glutamic Acid Sufficient for Pharmaceutical Intermediate Use?

Specifications must be evaluated case-by-case. For an intermediate used in the synthesis of an enantiopure active pharmaceutical ingredient, enantiomeric composition is as important as total chromatographic purity. A certificate of analysis reporting only assay and optical rotation 0.0° is not sufficient to confirm a 50:50 enantiomeric ratio; chiral HPLC or capillary electrophoresis with a cyclodextrin-based chiral selector is required. The appropriate system suitability parameters include resolution factor R_S and retention factor k′ determined according to USP 621 or Ph. Eur. 2.2.29. If the material is used in a GMP sequence, the process must demonstrate removal of the unwanted D or L configuration during subsequent isolation. Published data for every possible downstream configuration is limited; vendor process-development support and batch-specific impurity profiles are normally required.

In analytical method development, the product is used as an equimolar peak-pair reference for chiral separation. Injection of the racemate establishes elution order, linearity of peak area response, and resolution factor between the N-acetyl-L-glutamic acid and N-acetyl-D-glutamic acid peaks. Detection is normally performed at 210 nm because the molecule contains carboxyl and amide chromophores but no strong absorption above 260 nm. Typical reverse-phase methods use octadecylsilyl silica particles of 5 µm diameter with mobile phases containing 0.1% phosphoric acid or trifluoroacetic acid and an acetonitrile gradient. The racemate is not a certified reference material; if used for quantitative calibration, the laboratory should perform a purity assignment by mass-balance, quantitative NMR, or differential scanning calorimetry traceable to an appropriate calibration standard.

Enzymatic resolution of N-acetyl-DL-glutamic acid with aminoacylase I, classified as EC 3.5.1.14, is a well-established route to L-glutamic acid and N-acetyl-D-glutamic acid. The enzyme selectively hydrolyses the N-acetyl-L-glutamic acid fraction, leaving N-acetyl-D-glutamic acid. A preparative batch is typically operated at pH 7.5–8.5 and 37–42 °C in a stirred vessel equipped with pH-stat control. The liberation of the free amino acid consumes alkali, and failure to maintain pH above 7.0 reduces reaction rate. Separation is achieved by cation-exchange chromatography on strong acid resin; L-glutamic acid is retained under acidic loading conditions and eluted with dilute ammonia, while N-acetyl-D-glutamic acid passes through the column. The throughput of the immobilized-enzyme cartridge depends on enzyme load and substrate concentration, but specific cycle-life data for each resin carrier must be obtained from the enzyme supplier because published performance data for this exact substrate-carrier combination is limited.

Storage Stability and Hygroscopic Behaviour of the Crystalline Racemate

The crystalline product does not deliquesce under relative humidity below 60%, but powder caking may occur above 70% relative humidity because of surface moisture adsorption. Containers should be closed after each use and the material stored at 2–30 °C, with short excursions to 40 °C generally tolerated. A manufacturer-assigned retest period of 24 months is common when the material is stored under the stated conditions, with stability evaluation performed according to ICH Q1A(R2) principles. The product should not be milled in an uncontrolled atmosphere because static charging of fine particles creates a combustible dust hazard. Standard particulate controls for inert or nuisance dust under OSHA 29 CFR 1910.1000 Table Z-1 may apply, but no compound-specific occupational exposure limit has been established.

The material is incompatible with strong oxidising agents, strong aqueous bases, and acid chlorides. Under strongly alkaline conditions above pH 9, the acetamide group undergoes hydrolysis to regenerate DL-glutamic acid. Contact with primary amines at elevated temperatures should be avoided because the free carboxyl groups can undergo amide-forming coupling reactions. The product should not be combined with nitrite under acidic conditions because of the potential formation of N-nitroso derivatives, which is a relevant control in process streams where nitrite is used as a quenching agent.

When N-Acetyl-DL-Glutamic Acid Replaces N-Acetyl-L-Glutamic Acid in Biological and Analytical Assays

The substitution is not functionally transparent. In assays for carbamoyl phosphate synthetase I activation, the L enantiomer is the physiologically relevant allosteric activator. The N-acetyl-D-glutamic acid component of the racemate is not a biological equivalent. Consequently, a nominal concentration of 2 mmol L⁻¹ N-acetyl-DL-glutamic acid provides only 1 mmol L⁻¹ active L enantiomer if the D isomer is inert. Dose-response comparisons must therefore correct for the dilution effect. The product differs from N-acetyl-L-glutamic acid not only in optical rotation but also in crystallisation behaviour and melting characteristics. Racemic crystals may have lower lattice stability than the enantiopure L form, which affects dissolution rate and recrystallisation recovery in process simulators. Published data for some specific binary solvent crystallisation configurations is limited; laboratory verification is required before scale-up.

N-Acetyl-L-aspartic acid, CAS 997-55-7, differs from N-acetyl-DL-glutamic acid by side-chain length and biological function. The aspartate derivative is a central nervous system metabolite and magnetic resonance spectroscopy marker, whereas the glutamate derivative is used primarily as a protected amino acid building block and resolution substrate. The two compounds are not interchangeable in analytical methods; their molecular weights differ by 14 Da due to the additional methylene group in the glutamate backbone. If N-acetyl-DL-glutamic acid is evaluated as a matrix component for N-acetyl-L-aspartic acid methods, baseline chromatographic separation must be demonstrated and interference at the analyte retention time excluded.

For peptide synthesis, N-acetyl-DL-glutamic acid is mainly employed as a protected racemic intermediate. If the downstream sequence requires enantiopure L or D glutamic acid, the racemate must be resolved before coupling or the resulting diastereomeric peptides must be separated. The acetyl group is stable to acidolytic conditions used for tert-butoxycarbonyl removal but is removed under basic or enzymatic conditions. The α-acetamido group suppresses zwitterion-mediated crystallisation and permits solvent extraction of the free acid into ethyl acetate at pH 2.5, a property that is exploited in preparative resolution work. The workflow is distinct from that of N-acetyl-L-glutamic acid, which is isolated as a metabolic intermediate and may require freeze-drying to avoid degradation. No single processing route is universally suitable; each downstream use requires qualification of residual solvents, enantiomeric excess, particle size, and physical form against the intended process standard.

Process-scale equipment behaviour varies with trace impurity content. High residual chloride increases corrosion risk in stainless steel vessels under acidic conditions, while elevated loss on drying shifts charge weight corrections. For batch charging, the net weight should be corrected for loss on drying and residue on ignition only when the route is sensitive to ash content. In catalytic hydrogenation or metal-catalysed coupling steps, heavy metal and sulfur impurities in the bulk product must be controlled below the threshold specified by the catalyst supplier. Published data for this specific racemate in a universal formulation does not exist; acceptance limits are route-specific and should be derived from process capability studies.

Regulatory status differs from N-acetyl-L-glutamic acid and carglumic acid. The racemic DL form is not designated as an approved drug substance in the United States or Europe and is not the subject of a USP monograph. It is used as a laboratory reagent and synthetic intermediate rather than as a direct pharmaceutical ingredient. If the material is intended for use in a commercial drug manufacturing route, the manufacturer must qualify it under current good manufacturing practice, including full characterization of the enantiomeric composition, impurity profile, and residual solvent content, using validated test methods. The racemate is therefore a process chemical with a defined analytical envelope rather than a direct substitute for enantiopure N-acetyl-L-glutamic acid in biological or pharmaceutical applications.